Journal of Antimicrobial Chemotherapy (2001) 48, 97-103
© 2001 The British Society for Antimicrobial Chemotherapy
Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients
a Department of Hematology, University Hospital Gasthuisberg, B-3000 Leuven; b University St Jan's Hospital, Bruges; c University Hospital, Antwerp, Edegem; d University Hospital Sart Tilman, Liège; e Saint-Luc University Hospital, Brussels; f University Hospital, Gent; g University Hospital, Antwerp; h Janssen Research Foundation, Beerse, Belgium
The efficacy and safety of itraconazole oral solution and a combination of amphotericin B capsules plus nystatin oral suspension were compared in the prophylaxis of fungal infections in neutropenic patients. In an open, randomized, multicentre trial, 144 patients received itraconazole oral solution 100 mg bd, and 133 patients received amphotericin B 500 mg tds plus nystatin 2 MU qds. Overall, 65% of itraconazole-treated patients were considered to have had successful prophylaxis, compared with 53% in the polyene group. Proven deep fungal infections occurred in 5% of patients in each group. Fewer patients receiving itraconazole than amphotericin plus nystatin had superficial infections (3 versus 8%; P = 0.066). This trend in favour of itraconazole was seen in patients with profound neutropenia (neutrophil count <0.1 x 109 cells/L at least once) or prolonged neutropenia (neutrophil count <1.0 x 109 cells/L for >14 days). The median time to prophylactic failure was longer in the itraconazole group (37 days) than in the polyene group (34 days). The number of patients with fungal colonization (nose, sputum, stool) changed more favourably from baseline to endpoint in the itraconazole group than in the polyene group. Both treatments were safe and well tolerated; however, patients receiving amphotericin plus nystatin had a higher incidence of nausea and rash. In conclusion, itraconazole oral solution at doses of 100 mg bd and oral amphotericin B plus nystatin have similar prophylactic efficacy against fungal infections in neutropenic patients. On the basis of reduced incidence of superficial fungal infections, fungal colonization and specific adverse events, itraconazole may be the preferred treatment.
* Corresponding author. Tel: +32-16-34-68-80; Fax: +32-16-34-68-81; E-mail: marc.boogaerts{at}med.kuleuven.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Robenshtok, A. Gafter-Gvili, E. Goldberg, M. Weinberger, M. Yeshurun, L. Leibovici, and M. Paul Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis J. Clin. Oncol., December 1, 2007; 25(34): 5471 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dabur, T. K. Mandal, and G. L. Sharma Post-antifungal effects of the antifungal compound 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate on Aspergillus fumigatus J. Med. Microbiol., June 1, 2007; 56(6): 815 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Penack, S. Schwartz, P. Martus, M. Reinwald, M. Schmidt-Hieber, E. Thiel, and I. W. Blau Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial Ann. Onc., August 1, 2006; 17(8): 1306 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Glasmacher, O. Cornely, A. J. Ullmann, U. Wedding, H. Bodenstein, H. Wandt, C. Boewer, R. Pasold, H.-H. Wolf, M. Hanel, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia J. Antimicrob. Chemother., February 1, 2006; 57(2): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients J. Clin. Oncol., December 15, 2003; 21(24): 4615 - 4626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Cornely, A. J. Ullmann, and M. Karthaus Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies Blood, May 1, 2003; 101(9): 3365 - 3372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Lewis, R. A. Prince, J. Chi, and D. P. Kontoyiannis Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3208 - 3214. [Abstract] [Full Text] [PDF]
|
|